Erythropoietin Reduces Acute Lung Injury and Multiple Organ Failure/Dysfunction Associated to a Scald-Burn Inflammatory Injury in the Rat

• Type: Article in International Scientific Journal
• Date: 2015

Authors

Rocha, J (Author) Other; Eduardo Figueira, M (Author) Other; Barateiro, A (Author) Other; Fernandes, A (Author) Other; Brites, D (Author) Other; Pinto, R (Author) Other; Freitas, M (Author) Other; Eduarda Fernandes (Author) FFUP; Mota Filipe, H (Author) Other; Sepodes, B (Author) Other

Journal

Title: Inflammation

Vol. 38

Pages: 312-326

ISSN: 0360-3997

Publisher: Springer Nature

Indexing

ISI Web of Knowledge - 18 Citations

Scopus - 20 Citations

Other information

Authenticus ID: P-00G-16W

DOI: 10.1007/s10753-014-0035-7

Abstract (EN): Erythropoietin (EPO) is an endogenous regulator of erythropoiesis and is given exogenously as a replacement therapy for selected red blood cell disorders. In the past years, EPO has been emerging as a multifunctional, cytoprotective cytokine with anti-apoptotic, anti-inflammatory, and immunomodulatory properties. We aimed to evaluate the cytoprotective effect of rhEPO (recombinant human EPO) treatment on a rat model of multiorgan dysfunction induced by thermal injury. rhEPO was administered at 1000 U/kg (i.v.) 5 min prior to induction of injury and significantly reduced multiorgan dysfunction markers (liver, kidney, lung, serum cytokine levels). In the lung, rhEPO reduced: histological signs of tissue injury, inflammatory/injury markers on the bronchoalveolar fluid, neutrophil chemotaxis/infiltration, GSK-3 beta activation, and apoptosis. Our study showed that erythropoietin has the potential to exhibit pleiotropic cytoprotective effects and that it might be an interesting pharmacological strategy in the modulation of acute lung injury, such as the one associated to severe burn.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 15